Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
The Lancet HaematologyPublished 20 April 2015Open access
Koji Sasaki, Sara S. Strom, Susan O’Brien, Elias Jabbour, Farhad Ravandi, Marina Konopleva
Citations299
SJR quartileQ1
SJR score4.94
SNIP4.35
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveWill appear once the snapshot is generated
MethodsWill appear once the snapshot is generated
PopulationWill appear once the snapshot is generated
Sample sizeWill appear once the snapshot is generated
OutcomesWill appear once the snapshot is generated
ResultsWill appear once the snapshot is generated
LimitationsWill appear once the snapshot is generated
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
It is possible that most patients with CML can enjoy a near normal life expectancy with access to TKI, and the 10-year relative OS derived from the imatinib cohort is favorable, and it is reasonable to expect that the results will remain at least as favorable with additional follow-up observation with dasatinib or nilotinib.
Abstract
MD Anderson Cancer Center, National Cancer Institute.
Keywords
Medicine
New England Journal of MedicineFive-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
3,481 Citations2006Brian Druker, François Guilhot +30 more
After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients.
BloodEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
1,989 Citations2013Michele Baccarani, Michael Deininger +30 more
Optimal responders to chronic myeloid leukemia treatment should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved.
PubMedUnited States Life Tables, 2017.
805 Citations2019Elizabeth Arias, Jiaquan Xu
This report presents complete period life tables for the United States by race, Hispanic origin, and sex, based on age-specific death rates in 2017, and the overall expectation of life at birth was 78.6 years, decreasing from 78.7 in 2016.
New England Journal of MedicinePonatinib in Refractory Philadelphia Chromosome–Positive Leukemias
758 Citations2012Jörge E. Cortes, Hagop M. Kantarjian +14 more
Ponatinib was highly active in heavily pretreated patients with Ph-positive leukemias with resistance to tyrosine kinase inhibitors, including patients with the BCR-ABL T315I mutation, other mutations, or no mutations.
BloodDasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)
605 Citations2011Hagop M. Kantarjian, Neil P. Shah +18 more
Primary data showed superior efficacy for dasatinib compared with imatinib after 12 months, including significantly higher rates of complete cytogenetic response (CCyR), confirmed CCyR (primary end point), and major molecular response (MMR).
Journal of Clinical OncologyCost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia
495 Citations2013Stacie B. Dusetzina, Aaron N. Winn +3 more
A critical need to reduce patient costs for TKI adherence and discontinuation is suggested, as patients with higher copayments are more likely to discontinue or be nonadherent to TKIs.
Journal of Clinical OncologyBosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial
469 Citations2012Jörge E. Cortes, Dong‐Wook Kim +9 more
This ongoing trial did not meet its primary end point of CCyR at 12 months, despite the observed higher MMR rate at 12 years, faster times to CCyr and MMR, fewer on-treatment transformations to accelerated/blast phase, and fewer CML-related deaths with bosutinib compared with imatinib.
United States Life Tables, 2021
378 Citations2023Elizabeth Arias, Jiaquan Xu +1 more
This report presents period life tables for the United States based on age-specific death rates in 2004, which show increases in life expectancy for males and females, and for both the white and black populations.
BloodImproved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
338 Citations2012Hagop M. Kantarjian, Susan O’Brien +13 more
Survival in CML has significantly improved since 2001, particularly so in CP-AML and AP-CML, and Imatinib therapy minimized the impact of known prognostic factors and Sokal risk in CP -CML and accentuated theimpact of age in AP- and BP-C ML.
Journal of Clinical OncologyMortality After Cure of Testicular Seminoma
287 Citations2004Gunar K. Zagars, Matthew T. Ballo +2 more
Long-term survivors of seminoma treated with post-orchiectomy XRT are at significant excess risk of death as a result of cardiac disease or second cancer, and management strategies that minimize these risks but maintain the excellent hitherto observed cure rates need to be actively pursued.
Journal of Clinical OncologyResults of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia
248 Citations2009Jörge E. Cortes, Dan Jones +9 more
Dasatinib is an effective agent for the initial management of CML in early chronic phase, producing high rates of CCyR and MMR.
Journal of Clinical OncologyNilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
245 Citations2009Jörge E. Cortes, Dan Jones +9 more
Nilotinib is an effective option for the initial management of CML in early chronic phase, producing high rates of CCyR and MMR, with most patients reaching these responses early during their therapy.
CancerComplete cytogenetic and molecular responses to interferon‐α‐based therapy for chronic myelogenous leukemia are associated with excellent long‐term prognosis
225 Citations2003Hagop M. Kantarjian, Susan O’Brien +11 more
Little is known regarding long‐term prognosis among patients with Philadelphia chromosome (Ph)‐positive chronic myelogenous leukemia (CML) who achieve a complete cytogenetic response (0% Ph‐positive cells) after treatment with interferon‐α.
PubMedUnited States Life Tables, 2021.
222 Citations2010Elizabeth Arias, Jiaquan Xu +1 more
The 2006 life tables were estimated using a recently revised methodology first applied to the final annual U.S. life tables series with the 2005 edition and replace all previously published life tables for years 2000-2004.
BloodSurvival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia
206 Citations2006Hagop M. Kantarjian, Moshe Talpaz +9 more
Survival rates with imatinib mesylate were significantly better than with interferon-alpha within each of the CML prognostic risks groups, suggesting that the survival benefit of imatinIB mesylates (versus interfer on-alpha in newly diagnosed CML) is through improving cytogenetic response.
PubMedUnited States life tables, 2000.
196 Citations2002Elizabeth Arias
This report presents period life tables for the United States based on age-specific death rates in 2000, which show life expectancy increased for both males and females and for both the white and black populations between 1999 and 2000.
PubMedUnited States life tables, 2002.
190 Citations2004Elizabeth Arias
This report presents period life tables for the United States based on age-specific death rates in 2002 based on 2002 final mortality statistics, population estimates based on the 2000 decennial census and data from the Medicare program.
PubMedUnited States life tables, 1998.
172 Citations2001Robert N. Anderson
The life tables in this report are current life tables for the United States based on age-specific death rates in 1998, and life expectancy increased from 1997 to 1998 for each of the four race-sex groups for which life expectancy is reported.
BloodDelayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
165 Citations2009Alfonso Quintás‐Cardama, Hagop M. Kantarjian +7 more
The results suggest that patients not in CCyR after 12 months on imatinib have a higher risk of progression, discernible as early as 3 months into imatinIB therapy by molecular analysis and may provide the rationale to institute therapies that render higher rates of early response.
BloodTyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry
127 Citations2013Martin Höglund, Fredrik Sandin +18 more
Patients living in university vs nonuniversity catchment areas more often received tyrosine kinase inhibitors up front but showed comparable survival, and high-risk scores were significantly linked to inferior overall and relative survival.
BloodMalignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies
104 Citations2011Dushyant Verma, Hagop M. Kantarjian +8 more
No evidence at the moment suggests that exposure to TKIs increases the risk of developing second cancers, and second cancers occur in a small percentage of patients receiving therapy with TKI for hematologic malignancies, mostly CML.
LeukemiaManagement of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
102 Citations2010Elias Jabbour, Michael W. Deininger +1 more
Side effects that occur during treatment with imatinib, nilotinib or dasatinib—the currently approved TKI treatments for chronic myeloid leukemia—are described, including class effects and key differences in safety profiles.
PubMedUnited States life tables, 2008.
102 Citations2012Elizabeth Arias
This report presents complete period life tables for the United States by race, Hispanic origin, and sex, based on age-specific death rates in 2008, which showed life expectancy at birth increased for all groups considered, although approximately 0.1 years of the increase is due to the change in methodology.
BloodNilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
97 Citations2013Andreas Hochhaus, Giuseppe Saglio +12 more
Overall, nilotinib led to fewer treatment-emergent BCR-ABL mutations than imatinib and reduced rates of progression to AP/BC in patients with these mutations.
The Lancet HaematologyLong-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials
82 Citations2015Preetesh Jain, Hagop M. Kantarjian +12 more
Treatment with imatinib 800 mg or the second-generation TKIs dasatinib or nilotinib resulted in superior and deeper responses than did standard-dose imatinIB, which were maintained after 5 years of follow-up, although more patients discontinued therapy.
PubMedUnited States life tables, 2007.
79 Citations2011Elizabeth Arias
This report presents complete period life tables by race, Hispanic origin, and sex for the United States based on age-specific death rates in 2007, representing an increase of 0.2 years from life expectancy in 2006.
BloodPredictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
73 Citations2010Elias Jabbour, Hagop M. Kantarjian +8 more
Patients with poor performance status and no previous cytogenetic response to imatinib therapy have a low likelihood of responding to second-generation TKI with poor event-free survival and therefore should be offered additional treatment options.
CancerTrends in all‐cause mortality among patients with chronic myeloid leukemia
69 Citations2013Andrew M. Brunner, Federico Campigotto +5 more
A retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER) database to assess 5‐year overall survival (OS) in various patient age groups for chronic myeloid leukemia.
Journal of Clinical OncologySignificance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response
68 Citations2009Hagop M. Kantarjian, Jianqin Shan +5 more
Patients with chronic myelogenous leukemia who are in complete cytogenetic response (CGCR) on therapy and who lose a MMR or never achieve a MMR, and have more than 1 log increase of QPCR, should be monitored more closely and may be evaluated for mutations of BCR-ABL kinase domain.
United States Life Tables, 2024
65 Citations2026Elizabeth Arias, Jiaquan Xu +1 more
This report presents complete period life tables for the United States by race, Hispanic origin, and sex based on age-specific death rates in 2009, which shows life expectancy at birth increased for all groups considered between 2008 and 2009.
BloodChanges in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study
35 Citations2011Sélim Corm, Laurent Roche +9 more
Different effects according to Sokal scores of the use of imatinib on mortality in patients with chronic-phase CML were shown and it was shown that since 2000 the pattern of mortality of high-risk patients became similar to that of intermediate-risk ones.
European Journal Of HaematologyTreatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 - a report from the population-based CAMELIA Registry
33 Citations2011Edgar Faber, Jan Mužı́k +12 more
The ability to achieve results comparable to those of previous clinical studies in the CML cohort was influenced by centralised care, and comorbidities may limit the treatment potential of imatinib in the elderly.
Journal of Hematology & OncologyPopulation level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century
20 Citations2013the GEKID Cancer Survival Working Group, Dianne Pulte +9 more
Five-year survival estimates were higher in the US than in Germany overall, but the difference was only significant for ages 50–59 years, and strong improvement in survival was seen between 2002 and 2006.
Clinical Lymphoma Myeloma & LeukemiaSimilar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials
6 Citations2013Musa Yılmaz, Hagop M. Kantarjian +10 more
It is suggested that patients with CML treated outside of a clinical trial might have the same excellent outcome as those treated in aclinical trial provided they are followed with the same rigor.
BloodBaseline Characteristics Of Patients With Chronic Myeloid Leukemia In a Prospective Observational Study (SIMPLICITY)
4 Citations2013Jörge E. Cortes, Rüdiger Hehlmann +12 more
Overall, the SIMPLICITY population is older with potentially moreComorbidities than patients enrolled in first-line clinical trials with restrictive inclusion criteria, and initial TKI selection does not appear to be driven by baseline comorbidity, rather by perceived effectiveness, cost and familiarity.
BloodUnderstanding United States (US) Treatment Practices for the Management of Chronic Myeloid Leukemia (CML) in Clinical Practice: A US Subgroup Analysis of the WORLD CML Registry.
4 Citations2012Róbert Hermann, Carole B. Miller +6 more
In the US, many pts treated with first-line imatinib did not have routine molecular or cytogenetic assessments, suggesting that many US physicians do not monitor their patients as recommended by the NCCN guidelines.